The TAVR wars heated significantly at the annual meeting of the American College of Cardiology, where a new set of data for the Corevalve series of devices demonstrated that the Dublin-based Medtronic plc offering beats surgical aortic valve replacement on several scores for intermediate-risk patients, a population already served by a TAVR offering from Edwards Lifesciences Corp. of Irvine, Calif. Read More
